4.7 Letter

Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Related references

Note: Only part of the references are listed.
Article Hematology

Unique features of primary myelofibrosis in Chinese

Zefeng Xu et al.

BLOOD (2012)

Article Medicine, General & Internal

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srdan Verstovsek et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

The Prevention and Treatment of Missing Data in Clinical Trials

Roderick J. Little et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Letter Medicine, General & Internal

Need to realign patient-oriented and commercial and academic research

Alessandro Liberati

LANCET (2011)

Letter Medicine, General & Internal

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

Ayalew Tefferi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Article Medicine, General & Internal

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.

Srdan Verstovsek et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Oncology

Hypothesis: How do JAK2-inhibitors work in myelofibfosis

Ruben Mesa et al.

LEUKEMIA RESEARCH (2009)